Ixazomib citrate
In Stock•Starting at $24 for 100 mg•Purity ≥ 97%
| CAS No. | 1239908-20-3 |
|---|---|
| MDL No. | MFCD29767859 |
| MF | C20H23BCl2N2O9 |
| MW | 517.10 |
| InChI Key | MBOMYENWWXQSNW-AWEZNQCLSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 100 mg | 97% | $24 | In Stock | |
| 250 mg | 97% | $41 | In Stock | |
| 1 g | 97% | $155 | In Stock | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Ixazomib citrate is a glycine derivative formed by the amide linkage between the carboxy group of N-(2,5-dichlorobenzoyl)glycine and the amino group of 2,2'-{2-[(1R)-1-amino-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid. It serves as a prodrug for ixazomib, used in combination therapy for multiple myeloma. It functions as a proteasome inhibitor, antineoplastic agent, apoptosis inducer, and is classified as a prodrug, orphan drug, benzamide, dichlorobenzene, oxo dicarboxylic acid, and 1,3,2-dioxaborolane. It is functionally related to ixazomib.
| CAS No. | 1239908-20-3 |
|---|---|
| Product Name | Ixazomib citrate |
Biological Targets
PSMD1·PSMB2·PSMB1·PSMB5·PSMB8·
Associated Conditions
acute lymphoblastic leukemia·AL amyloidosis·Waldenstrom macroglobulinemia·acute myeloid leukemia·Kaposi's sarcoma·
* The information provided here is compiled from public sources and is for reference only.
